The European and Developing Countries Clinical Trials Partnership (EDCTP) has established itself as the focal point of cooperation in clinical research on infectious disease between the EU and sub-Saharan Africa. To continue these investments after the last calls of the EDCTP2 programme, there is a need to further support research on the major infectious disease threats facing sub-Saharan Africa. Despite large-scale investments in product development for poverty-related infectious diseases (PRDs), progress in achieving public health gain is slow, while sub-Saharan Africa bears the highest burden of these diseases. There is a need to support product development and to encourage the use of new, innovative approaches and emerging technologies in sub-Saharan Africa to achieve rapid progress and impact. The COVID-19 pandemic is generating novel knowledge that could also advance prevention, treatment or diagnosis of PRDs in this part of the world.
Proposals should address all of the following:
- Any PRD disease or group of PRDs affecting sub-Saharan Africa (within the scope of EDCTP2[[https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32014D0556&from=GA ]] or the proposed EDCTP3 and its draft strategic research and innovation agenda[[https://ec.europa.eu/info/sites/info/files/research_and_innovation/funding/documents/edctp3_draft_proposal_14_august_2020.pdf]]).
- Combine health technologies with other scientific areas such as mobile technologies and digital technologies (mHealth and eHealth), big data processing, and other emerging technologies.
- Implement one or more medium-scale clinical trials and/or clinical research studies that can deliver the proof-of-concept or validate smart, highly innovative health technologies or concepts to prevent, treat or diagnose PRDs in sub-Saharan Africa, drawing lessons from the COVID-19 experience.
- Increase collaboration with investors in development cooperation and international partnerships to create solutions for improved development or delivery of medical interventions for vulnerable populations in low-resource settings.
- Proposals involving pharmaceutical companies and small- or medium-sized enterprises (SMEs) are encouraged.
- Develop solutions that are easily integrated or linked to existing electronic or digital systems that are used in the implementation of clinical research and health systems’ patient management.
- Include activities that promote collaboration with ongoing and future EDCTP projects. In this context the granting authority may share project-relevant information with the EDCTP Association and the future EDCTP3 Joint Undertaking.
- Promote the integration of research work and health care service delivery.